Vantive debuts as standalone business amid complex landscape of chronic kidney disease

Vantive, formerly Baxter’s Kidney Care business, has officially launched as a standalone company. The move follows Baxter’s completion of the $3.8 billion sale of its Kidney Care business to private equity firm Carlyle Group on 31 January 2025, after the agreement was first struck in August last year.

Leading Vantive’s operations in Australia and New Zealand is Matthew Bain, previously the head of Baxter’s Kidney Care business in ANZ, now stepping into the role of General Manager. Steven Flynn, who has spent two decades at Baxter and most recently served as SVP & President for Asia Pacific, will oversee Vantive’s regional operations as President of Vantive Asia Pacific.

“This is an exciting day for our teams across Australia and New Zealand who will build on our 70-year legacy as a leader in kidney care to advance our Vantive mission to extend lives and expand possibilities. Through our partnerships with local hospitals, governments and clinicians we will continue to empower patients and care teams and begin a new era of innovation in dialysis and intensive care,” said Bain.

The launch of Vantive comes amid growing challenges in chronic kidney disease. According to the Australian Organ Waiting List, the number of patients waiting for a kidney transplant has risen from 1,377 in January 2024 to 1,426 just a year later.

Chris Forbes, CEO of Kidney Health Australia, remains steadfast in the advocacy group’s mission to reduce the waitlist and ultimately End Dialysis by 2050 by driving increased kidney transplants.

“A dialysis patient recently told me that when their mobile phone rings and displays NoCallerID, a wave of emotion comes over them as their unit does not display a number and it could be a call for a new kidney. Imagine riding that wave, that experience, every day,” Forbes recalled.

He added, “Dialysis as a treatment is invasive, time-consuming, and has devastating impacts on people and their families. It’s not a good enough solution and should only be a last resort.”

Chris Toth, CEO of Vantive, reinforced the company’s commitment to transforming patient care.

“From patients beginning their dialysis journeys to clinicians fighting to save lives in the ICU, accessing the right therapy at the right time is critical. This is why our singular focus as Vantive is to empower more patients and care teams in these moments – with better options, greater control and expanded possibilities,” he said.

“We are beginning a new era of vital organ therapy innovation, and I am looking forward to working with our 23,000 global Vantive colleagues to make a difference for millions of patients and families around the world.”

In reimagining healthcare across the entire patient journey, Health Industry Hub^TM is the only one-stop-hub uniting the diversity of the Pharma, MedTech, Diagnostics & Biotech sectors to inspire meaningful change.

The Health Industry Hub^TM content is copyright protected. Access is available under individual user licenses. Please click here to subscribe and visit T&Cs here.